Solanezumab for Alzheimer’s: Scientists are hopeful
Eli Lilly and Co. (Lilly) recently released additional data from two Phase 3 clinical trials of solanezumab for mild to moderate Alzheimer’s disease. In addition, scientists at the Alzheimer’s Disease Cooperative Study (ADCS) reported...